Taiho Oncology, Inc., and Cullinan Therapeutics, Inc., today announced new data from the central nervous system (CNS) ...

The authors describe an interesting approach to studying the dynamics and function of membrane proteins in different lipid environments. The important findings have theoretical and practical ...

Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM), a leader in the development of differentiated targeted radiotherapies, today announced that the first-ever preclinical data from its ATNM-400 ...

Zipalertinib shows 31% intracranial response and good tolerability in CNS-involved EGFR-mutated lung cancer, data presented ...

Kelun-Biotech has picked up another first for its TROP2-targeting antibody-drug conjugate (ADC) sacituzumab tirumotecan ...

Discover how AKIGAI’s EGFR inhibitors may redefine neuropathic pain therapy and offer hope for complex regional pain syndrome ...

Aumolertinib had comparable efficacy to osimertinib when treating epidermal growth factor receptor ( EGFR )-mutant non-small ...

Current treatment options for EGFR-mutant lung cancer include oral therapy combinations with chemotherapy and emerging ...

"As of now, semaglutide is FDA-indicated for slowing chronic kidney disease progression, [but] our results suggest that ...

Lung cancer is the leading cause of cancer deaths in the U.S., according to the American Cancer Society. For people battling a certain type of lung cancer, there’s good news.

Poster presentation: Title: Preclinical evaluation of petosemtamab, an epidermal growth factor receptor (EGFR) and leucine-rich repeat-containing G protein-coupled receptor (LGR5) bispecific antibody, ...